CYCC - Cyclacel Pharmaceuticals Inc Stock Price, Fair Value and News

$0.32-0.01 (-3.03%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CYCC Price Action

Last 7 days

-11.1%

Last 30 days

-13.5%

Last 90 days

-67.3%

Trailing 12 Months

-91.1%

CYCC RSI Chart

CYCC Valuation

Market Cap

2.0M

Price/Earnings (Trailing)

-0.15

Price/Sales (Trailing)

27.19

EV/EBITDA

0.06

Price/Free Cashflow

-0.21

CYCC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CYCC Fundamentals

CYCC Revenue

Revenue (TTM)

74.0K

CYCC Earnings

Earnings (TTM)

-13.4M

Earnings Growth (Yr)

67.56%

Earnings Growth (Qtr)

39.91%

CYCC Profitability

EBT Margin

-21390.54%

Return on Equity

1.4K%

Return on Assets

-249.6%

Free Cashflow Yield

-466.11%

CYCC Investor Care

Shares Dilution (1Y)

645.94%

Diluted EPS (TTM)

-19.1

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	449.0K	80.0K	74.0K	0
2023	0	0	0	420.0K
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	150.0K
2016	1.6M	1.5M	987.0K	843.0K
2015	1.9M	1.8M	1.8M	1.9M
2014	1.3M	1.4M	1.8M	1.7M
2013	281.0K	519.0K	790.0K	1.1M
2012	668.0K	526.0K	400.0K	230.0K
2011	258.8K	405.5K	552.3K	699.0K
2010	0	0	0	112.0K
2009	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

CEO	Mr. Spiro George Rombotis
WEBSITE	cyclacel.com
SECTOR	Healthcare
INDUSTRY	Biotechnology

Cyclacel Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Cyclacel Pharmaceuticals Inc? What does CYCC stand for in stocks?

CYCC is the stock ticker symbol of Cyclacel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cyclacel Pharmaceuticals Inc (CYCC)?

As of Fri Dec 20 2024, market cap of Cyclacel Pharmaceuticals Inc is 2.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CYCC stock?

You can check CYCC's fair value in chart for subscribers.

Is Cyclacel Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether CYCC is over valued or under valued. Whether Cyclacel Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Cyclacel Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CYCC.

What is Cyclacel Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CYCC's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 27.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CYCC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cyclacel Pharmaceuticals Inc's stock?

In the past 10 years, Cyclacel Pharmaceuticals Inc has provided -0.591 (multiply by 100 for percentage) rate of return.